Cue Biopharma, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cue Biopharma, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2017 to Q3 2024.
  • Cue Biopharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $1.58M, a 23.6% decline year-over-year.
  • Cue Biopharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was -$816K, a 35.6% increase year-over-year.
  • Cue Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $8.18K, a 13.9% decline from 2022.
  • Cue Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $9.5K, a 99.9% decline from 2021.
  • Cue Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $11.5M, a 9.87% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$816K $1.58M -$490K -23.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$326K $1.76M -$282K -13.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$43.8K $1.95M -$52K -2.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $8.18K -$6.1M +$1.27M +17.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$1.27M $2.07M +$9K +0.44% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$1.28M $2.04M -$272K -11.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$1M $2M -$1.01M -33.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $9.5K -$7.37M -$10.3M -348% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 $10.4M $2.06M -$1.19M -36.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 $11.5M $2.31M -$545K -19.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $12.1M $3.01M +$575K +23.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $11.5M $2.97M +$692K +30.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-21
Q3 2021 $10.8M $3.25M +$752K +30.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $10.1M $2.85M +$330K +13.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $9.74M $2.44M -$739K -23.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $10.5M $2.28M +$289K +14.5% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-16
Q3 2020 $10.2M $2.5M +$1.06M +73.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $9.13M $2.52M +$1.2M +91.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $7.93M $3.18M +$1.41M +79.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $6.52M $1.99M -$16.7K -0.83% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 $6.54M $1.44M -$1.29M -47.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $7.83M $1.32M +$46K +3.61% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $7.78M $1.77M +$610K +52.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $7.17M $2.01M +$1.24M +160% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 $5.94M $2.73M +$1.98M +264% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $3.96M $1.28M +$568K +80.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $3.39M $1.16M +$615K +113% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $2.78M $774K Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 $751K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 $707K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 $543K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.